Improvement of Visuo-spatial Function Assessed by Raven’s Colored Progressive Matrices in Dementia with Lewy Bodies by Donepezil Treatment.
10.9758/cpn.2017.15.3.243
- Author:
Yuta YOSHINO
1
;
Takaaki MORI
;
Taku YOSHIDA
;
Yasutaka TOYOTA
;
Hideaki SHIMIZU
;
Jun Ichi IGA
;
Shusaku NISHITANI
;
Shu Ichi UENO
Author Information
1. Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Toon, Japan. taka960mori@gmail.com
- Publication Type:Original Article
- Keywords:
Lewy body dementia;
Cholinesterase inhibitors;
Raven's Colored Progressive Matrices;
Visual spatial processing
- MeSH:
Cholinesterase Inhibitors;
Cognition Disorders;
Dementia*;
Humans;
Lewy Bodies*;
Lewy Body Disease;
Spatial Processing;
Visual Perception
- From:Clinical Psychopharmacology and Neuroscience
2017;15(3):243-247
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Donepezil is used to improve cognitive impairment of dementia with Lewy bodies (DLB). Visuo-spatial dysfunction is a well-known symptom of DLB. Non-verbal Raven’s Colored Progressive Matrices (RCPM) were used to assess both visual perception and reasoning ability in DLB subjects treated with donepezil. METHODS: Twenty-one DLB patients (mean age, 78.7±4.5 years) were enrolled. RCPM assessment was performed at the time of starting donepezil and within one year after starting donepezil. RESULTS: There were significant improvements of RCPM in the total scores between one year donepezil treatment (p=0.013), in both Set A score (p=0.002) and Set AB score (p=0.015), but trend in the Set B score (p=0.083). CONCLUSION: Donepezil is useful for improving visuo-spatial impairment in DLB, but not for problem-solving impairment.
